Clinical Trials Directory

Trials / Completed

CompletedNCT04535323

Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer

A Phase I, Single Arm, Prospective Study to Evaluate the Treatment of Genitourinary Syndrome of Menopause With Platelet Rich Plasma (PRP) in Women With a History of Breast Cancer

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Mayo Clinic · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase I trial is to find out possible benefits and/or side effects of platelet rich plasma for the treatment of genitourinary syndrome of menopause in patients with stage 0-III breast cancer. Platelet rich plasma is produced by collecting approximately 60-90 ml (4-6 tablespoons) of blood from the vein in patients' arm. The blood is spun using a centrifuge that separates the plasma and red blood cells. This allows doctors to collect the platelet rich plasma that is then loaded into individual, sterile syringes for injection. Giving platelet rich plasma may help relief symptoms of genitourinary syndrome of menopause in patients with breast cancer.

Detailed description

PRIMARY OBJECTIVE: I. To determine the safety and feasibility of use of platelet rich plasma (PRP) treatment in breast cancer survivors with genitourinary syndrome of menopause (GSM). SECONDARY OBJECTIVE: I. To determine the preliminary efficacy in treatment of vaginal atrophy, urinary symptoms, assessment of sexual function, quality of life symptoms, and patient global impression of improvement and tolerability. OUTLINE: Patients receive platelet rich plasma via injection into the vaginal area. After completion of study treatment, patients are followed up for 6 months.

Conditions

Interventions

TypeNameDescription
OTHERQuality-of-Life AssessmentAncillary studies
OTHERQuestionnaire AdministrationAncillary studies
BIOLOGICALTherapeutic Autologous Platelet-rich PlasmaGiven via injection

Timeline

Start date
2020-09-23
Primary completion
2024-01-10
Completion
2024-01-10
First posted
2020-09-01
Last updated
2024-04-03

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04535323. Inclusion in this directory is not an endorsement.

Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer (NCT04535323) · Clinical Trials Directory